Nuvalent, Inc.

    Jurisdiction
    United States
    ISIN
    US6707031075 (NUVL)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    1 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€310.61M
    EBIT margin
    0.0%
    Net income
    -€294.59M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €23.23M +∞% -€351.82M +19.4%
    €154.55M +565.4% -€258.15M -26.6%
    €380.99M +146.5% -€69.30M -73.2%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Noci Darlene Chief Development Officer -4K $74.62 -$298.48K
    Porter James Richard President and CEO -27K $75.42 -$2.04M
    Pelish Henry E. Chief Scientific Officer -5.5K $74.85 -$411.67K
    Noci Darlene Chief Development Officer -4K $80.36 -$321.44K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 29K $2.04M +20K Buy

    Add to watchlist

    Notifications